Robbinsville, NJ, USA November 1, 2017 -- DCAT is pleased to announce that the slate of candidates recommended by DCAT’s Leadership Development Committee for the 2017-2018 Board of Directors and Advisory Council was approved by member company official delegates. Elected members will take office on November 1, 2017.
Leading the Board of Directors as president will be Joe Sutton, Global Director, Sourcing at Eli Lilly and Company. Joining him in the important work of developing and guiding the organization's plans and policies are:
First Vice President:
Paolo Magri, Senior Vice President, Business Development, Advitech SA
Second Vice President: Dr. Stephan Kutzer, CEO, Alcami Corporation
Third Vice President:
Sean Diver, Director, Business Development, Early Intermediates, Lonza AG.
The Board of Directors also welcomes several newly-elected directors, each serving a one-year term:
The DCAT Advisory Council consists of 18 member representatives serving three-year terms from various segments of the industry, with six members rotating on/off each year. The newly elected members below are charged with providing insights, guidance and expertise to the Board of Directors, as well as to the committees and task forces that they serve on.
In addition, the following individuals were appointed to complete unexpired terms on the Advisory Council:
The DCAT Program Management Council consists of the chairs of its standing committees which are charge with identifying the needs of the members, and managing initiatives consistent with the organization’s goals and objectives. The committee chairs are as follows:
The DCAT organization would also like to thank the following dedicated leaders who have given generously of their time and provided invaluable insights to help the organization better serve its member companies.
Board of Directors (completed terms)
Advisory Council (completed terms)
DCAT Sr. Communications & Technology Specialist
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.